Hememics Biotechnologies, developer of graphene-based biosensing technology, has announced the successful on-site demonstration of its ESAP™ (Electrostatic Sensing for Analyte Profiling) platform at KanPro Research, Inc., a premier protein science and biomanufacturing CRO founded by Dr. Philip Gao.
Following a successful initial blind study that established proof-of-concept, and a subsequent on-site demonstration confirming the ability of ESAP™ to deliver definitive antibody-antigen binding results in under one hour-using a low-cost, disposable graphene chip cartridge-KanPro Research has reportedly placed an immediate commercial trial order to integrate ESAP™ into its production and validation workflows.
Current validation workflows are said to rely on slow, interpretive colorimetric measurements. ESAP™ addresses these barriers by introducing a graphene-based electronic approach that is fast, objective, and affordable:
- Electronic Detection: The platform eliminates the need for enzymes, optics, pumps, or wash steps.
- Label-Free: Direct detection requires only one antibody binding event, not two.
- Speed: Delivers an objective result in < 60 minutes (vs. 2-4 days for blot-based QC).
- Accessibility: No capital equipment required (vs. $12k-$17k for imagers).
- Affordable Consumables: Simple reader and one-time use chip cartridge system priced within most research consumables spending thresholds, avoiding costly capital expenditure approvals.
By delivering definitive "Yes/No" binding results in under an hour, ESAP™ enables labs to validate reagents before they are used in costly experiments, significantly improving research outcomes and efficiency.
"The scientific community has long accepted that a significant portion of research reagents are unreliable, simply because the tools to check them were too slow or too expensive," said John L. Warden, Jr., CEO of Hememics Biotechnologies. "Our successful deployment with KanPro Research proves that ESAP™ can serve as the industry's quality-control gatekeeper-ensuring that only validated, high-performance antibodies enter the research pipeline."
"Demand for high-quality, reliable antibodies has never been higher, yet bottlenecks in validation continue to slow the entire industry," said Dr. Philip Gao, Founder & President of KanPro Research. "Hememics' ESAP™ platform delivers the speed, cost-efficiency, and objectivity our field has been missing. In our workflow, ESAP can easily eliminate up to 75% of the time required for blot-based methods, while providing a definitive binding answer in under an hour-without gels, washes, or imaging-could reshape antibody QC, hybridoma screening, and even upstream bioprocess analytics. We are excited to be among the first adopters."
